Candriam SCA’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-142,963
| Closed | -$1.62M | – | 889 |
|
|
2022
Q2 | $1.62M | Hold |
142,963
| – | – | 0.01% | 547 |
|
|
2022
Q1 | $4.27M | Sell |
142,963
-79,207
| -36% | -$2.37M | 0.03% | 379 |
|
|
2021
Q4 | $5.89M | Hold |
222,170
| – | – | 0.04% | 328 |
|
|
2021
Q3 | $8.06M | Hold |
222,170
| – | – | 0.05% | 312 |
|
|
2021
Q2 | $9.64M | Buy |
+222,170
| New | +$9.64M | 0.07% | 291 |
|
|
2020
Q4 | – | Sell |
-28,000
| Closed | -$672K | – | 841 |
|
|
2020
Q3 | $672K | Sell |
28,000
-166,300
| -86% | -$3.99M | 0.01% | 676 |
|
|
2020
Q2 | $3.56M | Sell |
194,300
-50,000
| -20% | -$915K | 0.04% | 397 |
|
|
2020
Q1 | $5.11M | Hold |
244,300
| – | – | 0.06% | 338 |
|
|
2019
Q4 | $5.23M | Sell |
244,300
-3,500
| -1% | -$74.9K | 0.06% | 345 |
|
|
2019
Q3 | $4.63M | Buy |
+247,800
| New | +$4.63M | 0.06% | 334 |
|
|
2019
Q2 | – | Sell |
-247,800
| Closed | -$6.37M | – | 134 |
|
|
2019
Q1 | $6.37M | Hold |
247,800
| – | – | 0.08% | 270 |
|
|
2018
Q4 | $5.7M | Buy |
247,800
+21,000
| +9% | +$483K | 0.09% | 258 |
|
|
2018
Q3 | $7.28M | Buy |
226,800
+69,800
| +44% | +$2.24M | 0.1% | 246 |
|
|
2018
Q2 | $4.44M | Buy |
157,000
+6,500
| +4% | +$184K | 0.07% | 319 |
|
|
2018
Q1 | $5.33M | Buy |
150,500
+28,500
| +23% | +$1.01M | 0.09% | 271 |
|
|
2017
Q4 | $4.73M | Sell |
122,000
-4,500
| -4% | -$175K | 0.08% | 276 |
|
|
2017
Q3 | $3.21M | Buy |
126,500
+8,500
| +7% | +$216K | 0.06% | 361 |
|
|
2017
Q2 | $3.22M | Buy |
118,000
+9,500
| +9% | +$259K | 0.06% | 362 |
|
|
2017
Q1 | $3.59M | Buy |
108,500
+47,000
| +76% | +$1.56M | 0.07% | 331 |
|
|
2016
Q4 | $1.46M | Sell |
61,500
-11,000
| -15% | -$262K | 0.03% | 430 |
|
|
2016
Q3 | $2.66M | Buy |
+72,500
| New | +$2.66M | 0.06% | 301 |
|